Fulgent Genetics (FLGT) Common Equity (2015 - 2026)

Fulgent Genetics has disclosed Common Equity across 12 years of filings, most recently posting $1.0 billion for Q1 2026.

• Common Equity for Q1 2026 came in at $1.0 billion, down 6.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.0 billion (down 6.5% YoY), and the FY2025 annual result was $1.1 billion, down 1.52% from the prior year.
• Common Equity came in at $1.0 billion for Q1 2026 at Fulgent Genetics, down from $1.1 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $1.3 billion in Q1 2022 to a low of $1.0 billion in Q1 2026.
• The 5-year median for Common Equity is $1.1 billion (2023), against an average of $1.2 billion.
• Across the five-year window, Common Equity soared 63.8% in 2022 and dropped 11.21% in 2024, its largest moves.
• Fulgent Genetics' Common Equity stood at $1.3 billion in 2022, then decreased by 10.76% to $1.1 billion in 2023, then decreased by 0.36% to $1.1 billion in 2024, then retreated by 1.52% to $1.1 billion in 2025, then fell by 5.59% to $1.0 billion in 2026.
• The last three Common Equity figures came in at $1.0 billion (Q1 2026), $1.1 billion (Q4 2025), and $1.1 billion (Q3 2025), per Business Quant data.